[
    [
        {
            "time": "2023-04-12",
            "original_text": "4月12日有12家公司获重要股东增减持 *ST云网已被连续增持20次",
            "features": {
                "keywords": [
                    "重要股东",
                    "增减持",
                    "*ST云网",
                    "连续增持"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "餐饮",
                    "酒店"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "4月12日有12家公司获重要股东增减持 *ST云网已被连续增持20次",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-04-12",
            "original_text": "[买入评级]贝达药业(300558)年报点评：埃克替尼恢复增长 激励高价落地 期待新药不断兑现",
            "features": {
                "keywords": [
                    "贝达药业",
                    "埃克替尼",
                    "恢复增长",
                    "激励高价",
                    "新药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物技术"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[买入评级]贝达药业(300558)年报点评：埃克替尼恢复增长 激励高价落地 期待新药不断兑现",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-04-12",
            "original_text": "他们，为中国制造插上科学翅膀",
            "features": {
                "keywords": [
                    "中国制造",
                    "科学",
                    "创新"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "科技",
                    "制造业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "他们，为中国制造插上科学翅膀",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 4,
                "Impact": 2,
                "Duration": 3,
                "Entity_Density": 1,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        }
    ]
]